LBPH Pengajuan SEC - Longboard Pharmaceuticals, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1832168

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Longboard Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 14, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex-99-02142025110208.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State
February 14, 2025	EX-99.1	EXHIBIT A - JOINT FILING AGREEMENT EX-99.1 2 jointfilingagreement.htm EXHIBIT A - JOINT FILING AGREEMENT This joint filing agreement is made and entered into as of this 14th day of February, 2025, by and among Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andre
December 12, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-40192 Longboard Pharmaceuticals, Inc. (Exact name of registrant as speci
December 10, 2024	RW WD	Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 December 10, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C 20549 RE: Longboard Pharmaceuticals, Inc. Registration Statement on Form S-3ASR Filed March 12, 2024 File No. 333-277858 Withdrawal of Registration Withdrawal Request Previously
December 10, 2024	POSASR	As filed with the Securities and Exchange Commission on December 10, 2024 As filed with the Securities and Exchange Commission on December 10, 2024 Registration No.
December 2, 2024	EX-3.2	LONGBOARD PHARMACEUTICALS, INC. AMENDED AND RESTATED BY-LAWS ARTICLE I Exhibit 3.2 LONGBOARD PHARMACEUTICALS, INC. (Delaware) AMENDED AND RESTATED BY-LAWS ARTICLE I Offices Section 1.1 Registered Office. The corporation shall maintain a registered office and registered agent in the State of Delaware. The registered office and/or registered agent of the corporation may be changed from time to time by action of the board of directors. Section 1.2 Other Offices. The cor
December 2, 2024	S-8 POS	As filed with the Securities and Exchange Commission on December 2, 2024 As filed with the Securities and Exchange Commission on December 2, 2024 Registration No.
December 2, 2024	POS AM	As filed with the Securities and Exchange Commission on December 2, 2024 As filed with the Securities and Exchange Commission on December 2, 2024 Registration No.
December 2, 2024	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
December 2, 2024	EX-99.25	EX-99.25 Lbph-form25
December 2, 2024	S-8 POS	As filed with the Securities and Exchange Commission on December 2, 2024 As filed with the Securities and Exchange Commission on December 2, 2024 Registration No.
December 2, 2024	POS AM	As filed with the Securities and Exchange Commission on December 2, 2024 As filed with the Securities and Exchange Commission on December 2, 2024 Registration No.
December 2, 2024	RW	Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 December 2, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C 20549 RE: Longboard Pharmaceuticals, Inc. Application for Withdrawal of Registration Statement Form S-3ASR File No. 333-277858 Ladies and Gentlemen: Longboard Pharmaceuticals, Inc
December 2, 2024	EX-3.1	FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LONGBOARD PHARMACEUTICALS, INC. December 2, 2024 ARTICLE 1 Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LONGBOARD PHARMACEUTICALS, INC. December 2, 2024 ARTICLE 1 The name of the corporation is: Longboard Pharmaceuticals, Inc. (the “Corporation”). ARTICLE 2 The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of the Cor
December 2, 2024	POS AM	As filed with the Securities and Exchange Commission on December 2, 2024 As filed with the Securities and Exchange Commission on December 2, 2024 Registration No.
December 2, 2024	S-8 POS	As filed with the Securities and Exchange Commission on December 2, 2024 As filed with the Securities and Exchange Commission on December 2, 2024 Registration No.
December 2, 2024	S-8 POS	As filed with the Securities and Exchange Commission on December 2, 2024 As filed with the Securities and Exchange Commission on December 2, 2024 Registration No.
November 29, 2024	EX-99.(A)(5)(XIII)	CORPORATE RELEASE Exhibit (a)(5)(xiii) CORPORATE RELEASE Valby, Denmark, November 28, 2024 Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled • A significant step forward in Lundbeck’s Focused Innovator strategy and advancing the goal of building a robust neuro-rare franchise • The transaction is expected to close on December 2, 2024, following Lundbeck’s acceptance of all shares of common stock validly tendered and not validly withdrawn pursuant to the tender offer • Total transaction value of approximately USD 2.
November 29, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Co UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) LANGKAWI CORPORATION (Offeror) A Direct Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiar
November 29, 2024	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Longboard Pharmaceuticals, Inc. (Name of Subj UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longboard Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securit
November 20, 2024	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Longboard Pharmaceuticals, Inc. (Name of Subj UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longboard Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securit
November 20, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Co UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) LANGKAWI CORPORATION (Offeror) A Direct Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiar
November 15, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Co UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) LANGKAWI CORPORATION (Offeror) A Direct Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiar
November 15, 2024	EX-99.(A)(5)(XI)	Business update & financial results 9M 2024 Martha Living with depression Safe Harbor/Forward-Looking Statements 2 9M 2024 – November 13, 2024 This presentation contains forward-looking statements that provide our expectations or forecasts of future Exhibit (a)(5)(xi) Business update & financial results 9M 2024 Martha Living with depression Safe Harbor/Forward-Looking Statements 2 9M 2024 – November 13, 2024 This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.
November 15, 2024	EX-99.(A)(5)(XII)	1 Exhibit (a)(5)(xii) The following are excerpts from a transcript from Lundbeck A/S’s presentation held on November 13, 2024.
November 15, 2024	EX-99.(A)(5)(X)	9M 2024 Exhibit (a)(5)(x) CORPORATE RELEASE NOVEMBER 13, 2024 Financial report for the period January 1 to September 30, 2024 Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 Key highlights Lundbeck’s total revenue grew by +13% CER1 (+10% DKK) to DKK 16,463 million in the first nine months of 2024, with all regions contributing to growth • Unite
November 14, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-lbph093024a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Longboard Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 54300N103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 8, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 7, 2024	EX-99.1	Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates • Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years • Recently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet s
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longb
November 6, 2024	SC 14D9/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Longboard Pharmaceuticals, Inc. (Name of Subj UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longboard Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securit
November 6, 2024	SC TO-T/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Co UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) LANGKAWI CORPORATION (Offeror) A Direct Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiar
October 30, 2024	EX-99.(E)(3)	Confidentiality Agreement, dated as of February 2, 2024, by and between Longboard Pharmaceuticals, Inc. and H. Lundbeck A/S, as amended on June 29, 2024. Exhibit (e)(3) STRICTLY CONFIDENTIAL Lundbeck ref. CW187694 February 2, 2024 CONFIDENTIAL H. Lundbeck A/S Ottiliavej 9 DK 2500 Valby Denmark Attention: [●] Re: Project X – Confidentiality Agreement Ladies and Gentlemen: In connection with the consideration of a possible negotiated transaction or other negotiated business deal or negotiated arrangement (a “Transaction”) between Longboard Pharmaceut
October 30, 2024	SC TO-T	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) LA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) LANGKAWI CORPORATION (Offeror) A Direct Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiary of H. LUNDBECK A
October 30, 2024	EX-99.(B)(2)	SECTION 1 Exhibit (b)(2) Execution version Facility Agreement H. Lundbeck A/S CONTENTS 1 Definitions and Interpretation 3 2 The Facility 25 3 Purpose 27 4 Conditions of Utilisation 28 5 Utilisation 29 6 Repayment 30 7 Prepayment and Cancellation 30 8 Interest 35 9 Interest Periods 37 10 Changes to the Calculation of Interest 37 11 Fees 39 12 Tax Gross Up and Indemnities 40 13 Increased Costs 45 14 Other Ind
October 30, 2024	EX-99.(A)(1)(III)	Offer to Purchase for Cash All Outstanding Shares of Common Stock LONGBOARD PHARMACEUTICALS, INC. $60.00 Per Share LANGKAWI CORPORATION a direct wholly owned subsidiary of LUNDBECK LLC and an indirect wholly owned subsidiary of H. LUNDBECK A/S THE Exhibit (a)(1)(iii) Offer to Purchase for Cash All Outstanding Shares of Common Stock of LONGBOARD PHARMACEUTICALS, INC.
October 30, 2024	SC 14D9	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longb UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longboard Pharmaceuticals, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 54300N103 (CUSIP
October 30, 2024	EX-99.(E)(8)	Amended and Restated Employment Agreement, dated October 14, 2024, by and between Longboard Pharmaceuticals, Inc. and Kevin R. Lind. Exhibit (e)(8) Longboard Pharmaceuticals, Inc. October 14, 2024 Kevin Lind via email Re: Amended and Restated Offer Letter Dear Kevin: You are currently employed by Longboard Pharmaceuticals, Inc. (the “Company”) under the terms of an offer letter between you and the Company dated March 1, 2021 (the “Offer Letter”). The Company is amending and restating the terms of the Offer Letter to reflect you
October 30, 2024	EX-99.(D)(2)	[Signature page follows] Exhibit (d)(2) STRICTLY CONFIDENTIAL February 2, 2024 CONFIDENTIAL H. Lundbeck A/S Ottiliavej 9 DK 2500 Valby Denmark Attention: [●] Re: Project X – Confidentiality Agreement Ladies and Gentlemen: In connection with the consideration of a possible negotiated transaction or other negotiated business deal or negotiated arrangement (a “Transaction”) between Longboard Pharmaceuticals, Inc. (together w
October 30, 2024	EX-99.(B)(1)	STRICTLY CONFIDENTIAL – LEGAL PRIVILEGE Exhibit (b)(1) EXECUTION VERSION ADVOKATPARTNERSELSKAB STRICTLY CONFIDENTIAL – LEGAL PRIVILEGE SECOND AMENDMENT AND RESTATEMENT AGREEMENT TO A MULTICURRENCY REVOLVING FACILITY AGREEMENT DATED 25 JUNE 2019 (AS AMENDED AND RESTATED PURSUANT TO A FIRST AMENDMENT AND RESTATEMENT AGREEMENT DATED 5 AUGUST 2022) Between H.
October 30, 2024	EX-99.(E)(9)	Amended and Restated Employment Agreement dated October 14, 2024, by and between Longboard Pharmaceuticals, Inc. and Randall E. Kaye, M.D. Exhibit (e)(9) Longboard Pharmaceuticals, Inc. October 14, 2024 Randall E. Kaye, M.D. via email Re: Amended and Restated Offer Letter Dear Randall: You are currently employed under the terms of an offer letter between you and Longboard Pharmaceuticals, Inc. (the “Company”) dated March 17, 2022 (the “Offer Letter”). The Company is amending and restating the terms of the Offer Letter to reflect your
October 30, 2024	EX-99.(A)(1)(I)	Offer to Purchase for Cash All Outstanding Shares of Common Stock LONGBOARD PHARMACEUTICALS, INC. $60.00 Per Share LANGKAWI CORPORATION a direct wholly owned subsidiary of LUNDBECK LLC and an indirect wholly owned subsidiary of H. LUNDBECK A/S THE OF TABLE OF CONTENTS Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of LONGBOARD PHARMACEUTICALS, INC.
October 30, 2024	EX-99.(E)(10)	Amended and Restated Employment Agreement dated October 14, 2024, by and between Longboard Pharmaceuticals, Inc. and Brandi Roberts. Exhibit (e)(10) Longboard Pharmaceuticals, Inc. October 14, 2024 Brandi Roberts via email Re: Amended and Restated Offer Letter Dear Brandi: You are currently employed by Longboard Pharmaceuticals, Inc. (the “Company”) under the terms of an offer letter between you and the Company dated March 1, 2021 (the “Offer Letter”). The Company is amending and restating the terms of the Offer Letter to refle
October 30, 2024	EX-99.(A)(1)(V)	Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock LONGBOARD PHARMACEUTICALS, INC. $60.00 Per Share LANGKAWI CORPORATION a direct wholly owned subsidiary of LUNDBECK LLC and an indirect wholly owned subsidiary of H. LUNDBECK Exhibit (a)(1)(v) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
October 30, 2024	EX-99.(A)(1)(II)	LETTER OF TRANSMITTAL to Tender Shares of Common Stock LONGBOARD PHARMACEUTICALS, INC. $60.00 Per Share Pursuant to the Offer to Purchase Dated October 30, 2024 LANGKAWI CORPORATION a direct wholly owned subsidiary of LUNDBECK LLC and an indirect who Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of LONGBOARD PHARMACEUTICALS, INC.
October 30, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) LONGBOARD PHARMACEUTICALS, INC.
October 30, 2024	EX-99.(A)(1)(IV)	Offer to Purchase for Cash All Outstanding Shares of Common Stock LONGBOARD PHARMACEUTICALS, INC. $60.00 Per Share LANGKAWI CORPORATION a direct wholly owned subsidiary of LUNDBECK LLC and an indirect wholly owned subsidiary of H. LUNDBECK A/S THE OF Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of LONGBOARD PHARMACEUTICALS, INC.
October 25, 2024	EX-99.2	Focused innovation driving sustainable growth Lundbeck Capital Markets Event – October 23, 2024 Martha Living with depression and ADHD Safe Harbor/Forward-Looking Statements This presentation contains forward-looking statements that provide our expec Exhibit 99.2 Focused innovation driving sustainable growth Lundbeck Capital Markets Event – October 23, 2024 Martha Living with depression and ADHD Safe Harbor/Forward-Looking Statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking sta
October 25, 2024	EX-99.1	INVESTOR NEWS Exhibit 99.1 INVESTOR NEWS Valby, Denmark, October 23, 2024 Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth • Execution of the Focused Innovator strategy is well under way with key elements delivering good progress and laying foundation for long-term sustainable growth • Mid-term targets are adjusted by including 2027. Re
October 25, 2024	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGK UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGKAWI CORPORATION (Offeror) A Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiary of H. LUNDBECK A/S (Parent
October 25, 2024	EX-99.3	The following are excerpts from a transcript from Lundbeck A/S’s presentation held on October 23, 2024. Exhibit 99.3 The following are excerpts from a transcript from Lundbeck A/S’s presentation held on October 23, 2024. Charl van Zyl - President & CEO Before we continue, there is, of course, important Safe Harbour statements. The discussion today, of course, will include forward-looking statements that are, of course, subject to change. And also, importantly, we made, of course, an announcement las
October 16, 2024	EX-99.1	Forward-Looking Statements 1 This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements Exhibit 99.1 Forward-Looking Statements 1 This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and
October 16, 2024	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longb SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longboard Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 54300
October 16, 2024	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGK UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGKAWI CORPORATION (Offeror) A Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiary of H. LUNDBECK A/S (Parent
October 15, 2024	EX-99.4	EX-99.4 Exhibit 99.4
October 15, 2024	EX-99.1	Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline Exhibit 99.1 Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline • The proposed acquisition represents a significant step forward in Lundbeck’s Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medi
October 15, 2024	EX-99.3	Email from Charl van Zyl, President and Chief Executive Officer of Lundbeck, sent to all of Longboard’s employees, first used on October 14, 2024 (incorporated by reference to Exhibit 99.3 to Longboard’s Schedule 14D9-C, filed October 15, 2024 Exhibit 99.3 Email from Charl to Longboard employees. Subject: A message from Charl van Zyl, President and CEO of Lundbeck Dear Longboard Team, I hope this message finds you well. As you may have seen, we have just announced a definitive agreement for Lundbeck to acquire Longboard Pharmaceuticals. I understand this news might come as a surprise, especially on a Sunday night, so I want to extend my
October 15, 2024	EX-99.1	2 Exhibit 99.1 Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline • The proposed acquisition represents a significant step forward in Lundbeck’s Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medi
October 15, 2024	EX-99.2	Employee FAQ, first used on October 14, 2024 Exhibit 99.2 Frequently Asked Questions for Employees About the Transaction with Lundbeck 1. What was announced? • On October 14, 2024, Longboard Pharmaceuticals, Inc. and H. Lundbeck A/S entered into a definitive merger agreement for Lundbeck to acquire Longboard at a price of $60 in cash per share of Longboard common stock. • Under the terms of the merger agreement, Lundbeck will commence a tend
October 15, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
October 15, 2024	EX-99.1	Email from Kevin Lind, Chief Executive Officer of Longboard Pharmaceuticals, Inc., sent to all employees, first used on October 14, 2024 (incorporated by reference to Exhibit 99.1 to Longboard’s Schedule 14D9-C, filed October 15, 2024 Exhibit 99.1 PRIVILEGED AND CONFIDENTIAL All Employees Email for Transaction Announcement To: All Employees From: Kevin Lind Subject: Today’s Announcement Longboard team, As you may have seen, we just announced that Longboard Pharmaceuticals has entered into a merger agreement with H. Lundbeck A/S (Lundbeck) under which Lundbeck will acquire Longboard at a price of $60 per share. You can read our
October 15, 2024	EX-2.1	Agreement and Plan of Merger, dated as of October 14, 2024, by and among Longboard Pharmaceuticals, Inc., H. Lundbeck A/S, Langkawi Corporation and Lundbeck LLC. Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: H. Lundbeck A/S, a Danish aktieselskab; Langkawi Corporation, a Delaware corporation; Lundbeck LLC, a Delaware limited liability company; and Longboard Pharmaceuticals, Inc., a Delaware corporation. Dated as of October 14, 2024 TABLE OF CONTENTS Page SECTION 1. THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 SECTION 2. MERGER TR
October 15, 2024	EX-99.3	IMPORTANT INFORMATION FOR INVESTORS AND SECURITY HOLDERS Exhibit 99.3 Email from Charl to Longboard employees. Subject: A message from Charl van Zyl, President and CEO of Lundbeck Dear Longboard Team, I hope this message finds you well. As you may have seen, we have just announced a definitive agreement for Lundbeck to acquire Longboard Pharmaceuticals. I understand this news might come as a surprise, especially on a Sunday night, so I want to extend my
October 15, 2024	EX-99.2	EX-99.2 Exhibit 99.2
October 15, 2024	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGK UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGKAWI CORPORATION (Offeror) A Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiary of H. LUNDBECK A/S (Parent
October 15, 2024	EX-99.1	Lundbeck Acquisition Announcement 14th October, 2024 \| 10:00 CEST EX-99.1 2 ny20037200x2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Lundbeck Acquisition Announcement 14th October, 2024 \| 10:00 CEST Transcript Speakers: Charl van Zyl Joerg Hornstein Johan Luthman Maria Alfaiate 1 IMPORTANT INFORMATION FOR INVESTORS AND SECURITY HOLDERS The tender offer (the Offer) for the outstanding common stock of Longboard referred to in this transcript has not yet commenced. The des
October 15, 2024	SC TO-C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGK UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Subject Company) LANGKAWI CORPORATION (Offeror) A Wholly Owned Subsidiary of LUNDBECK LLC (Parent of Offeror) An Indirect Wholly Owned Subsidiary of H. LUNDBECK A/S (Parent
October 15, 2024	EX-99.4	Letter to third parties, first used on October 14, 2024 Exhibit 99.4 To: Third Parties Subject: Today’s Announcement Dear NAME, I am writing to share the exciting news (linked here) that H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals (Longboard) have entered into an agreement for Lundbeck to acquire Longboard. Together, we share a strong vision to advance treatments for neurological conditions and to transform the lives of patients and their
October 15, 2024	SC14D9C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longb SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Longboard Pharmaceuticals, Inc. (Name of Subject Company) Longboard Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 54300
August 1, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
August 1, 2024	EX-99.1	Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates • Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older • Bexicaserin demonstrated a sustained, durable response in seizure reduction
August 1, 2024	EX-10.2	Longboard Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.2 to Longboard’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed August 1, 2024). Exhibit 10.2 LONGBOARD PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY AMENDED AND RESTATED: MAY 23, 2024 Each member of the Board of Directors (the “Board”) of Longboard Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of to the Company or any of its subsidiaries and who is designated by the Board or the Compensation Committee of the Board as eligible t
August 1, 2024	EX-99.2	Forward-Looking Statements and Other Legal Notices This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities Corporate Presentation August 1, 2024 Exhibit 99.2 Forward-Looking Statements and Other Legal Notices This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; the potential of bexicaserin (LP352) and LP659, including to be best-in-class, to trea
August 1, 2024	EX-99.2	EX-99.2 1 L ON GB O A R D P H AR M A C E U T I C A L S Corporate Presentation AUGUST 1, 2024 Exhibit 99.
August 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
August 1, 2024	EX-10.1	Exhibit 10.1 Exhibit 10.1 Longboard Pharmaceuticals, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: February 28, 2021 Approved by the Stockholders: March 5, 2021 Amended and Restated by the Compensation Committee: October 19, 2023 Amended and Restated by the Compensation Committee: May 23, 2024 Table of Contents Page 1. General. 1 2. Shares Subject to the Plan. 1 3. Eligibility and Limitati
July 15, 2024	SC 13G	LBPH / Longboard Pharmaceuticals, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Longboard Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Numbe
July 1, 2024	EX-99.1	Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) Exhibit 99.1 Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352) • U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) LA JOLLA, Calif., July 1, 2024 – Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-st
July 1, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commiss
June 10, 2024	EX-99.1	Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) • Bexicaserin achieved a Exhibit 99.1 Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs) • Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants random
June 10, 2024	EX-99.2	EX-99.2 1 L ON GB O A R D P H AR M A C E U T I C A L S Bexicaserin (LP352) Open-Label Extension (OLE) Interim Analysis JUNE 10, 2024 Exhibit 99.
June 10, 2024	EX-99.2	Forward-Looking Statements This presentation (including verbal statements that may accompany it) contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: bexicaser Bexicaserin (LP352) Open-Label Extension (OLE) Interim Analysis June 10, 2024 Exhibit 99.
June 10, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commis
May 24, 2024	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40192) filed with the SEC on May 24, 2024). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LONGBOARD PHARMACEUTICALS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Longboard Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY
May 24, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
May 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
May 2, 2024	EX-10.1	Non-Voting Common Stock Purchase Agreement, dated March 26, 2024, by and between the Registrant and the Purchaser named therein. Exhibit 10.1 NON-VOTING COMMON Stock Purchase AgreemenT This Non-Voting Common Stock Purchase Agreement (this “Agreement”) is made as of March 26, 2024 by and between Longboard Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership (“Purchaser”). Whereas, subject to the terms and conditions set for
May 2, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commissi
May 2, 2024	EX-99.1	Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates • Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 • Presented late-breaking data for bexicaserin from the PACIFIC Study at the American Academy of Neurology (AAN) Annu
May 2, 2024	EX-3.2	Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Form 10-Q (File No. 001-40192) filed with the SEC on May 2, 2024). Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LONGBOARD PHARMACEUTICALS, INC. September 21, 2023 ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may b
April 15, 2024	EX-99.1	EX-99.1 BACKGROUND • DEEs are the most severe group of epilepsies and are characterized by drug-resistant seizures, epileptiform abnormalities, and developmental slowing or regression 1-3 • DEE trials have focused on patients with specific epilepsy syndromes, including Dravet Syndrome, tuberous sclerosis complex, and LGS; the latter has etiologic heterogeneity • Bexicaserin is a potent and selective 5-HT
April 15, 2024	EX-99.1	Longboard Pharmaceuticals poster titled “Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Participants with Developmental and Epileptic Encephalopathies: Results of the Phase 1b/2a PACIFIC Study” Exhibit 99.1
April 15, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
April 12, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 12, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 12, 2024	DEFA14A	COURTESY COPY OF LBPH_2024_ANN_MTG_NOTICE
March 28, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 26, 2024	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
March 12, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
March 12, 2024	EX-10.4	Longboard Pharmaceuticals, Inc. 2021 Equity Incentive Plan Exhibit 10.4 Longboard Pharmaceuticals, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: February 28, 2021 Approved by the Stockholders: March 5, 2021 Amended and Restated by the Compensation Committee: October 19, 2023 Table of Contents Page 1. General. 1 2. Shares Subject to the Plan. 1 3. Eligibility and Limitations. 3 4. Options and Stock Appreciation Rights. 4 5. Awards Othe
March 12, 2024	EX-4.9	Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.9 LONGBOARD PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF LONGBOARD PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking assoc
March 12, 2024	EX-97.1	Incentive Compensation Recoupment Policy Exhibit 97.1 Longboard Pharmaceuticals, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Longboard Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s re
March 12, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40192 Longboard Pharm
March 12, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Longboard Pharmaceuticals, Inc.
March 12, 2024	EX-4.5	Form of Indenture. Exhibit 4.5 LONGBOARD PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certifica
March 12, 2024	S-3ASR	As filed with the Securities and Exchange Commission on March 12, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 12, 2024 Registration No.
March 12, 2024	EX-10.6	Exhibit 10.6 Exhibit 10.6 Longboard Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (2021 Equity Incentive Plan) Longboard Pharmaceuticals, Inc. (the “Company”), pursuant to the Company’s 2021 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The
March 12, 2024	EX-99.2	Forward-Looking Statements and Other Legal Notices This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities Corporate Presentation March 12, 2024 Exhibit 99.2 Forward-Looking Statements and Other Legal Notices This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; anticipated milestones and timing; the prevalence of, unmet need associated with, and
March 12, 2024	S-8	As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No.
March 12, 2024	EX-4.8	Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 LONGBOARD PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF LONGBOARD PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o
March 12, 2024	EX-99.1	Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates Exhibit 99.1 Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates • Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) was reported in January • Announcing an update to the primary efficacy endpoint data previously reported in January, which show further improvemen
March 12, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Longboard Pharmaceuticals, Inc.
March 12, 2024	EX-4.10	Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.10 LONGBOARD PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF LONGBOARD PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking asso
February 14, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / Cormorant Asset Management, LP - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Longboard Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 54300N103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
February 14, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - LONGBOARD PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p24-0290sc13ga.htm LONGBOARD PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Longboard Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of
February 13, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / Prosight Management, LP - SC 13G/A Passive Investment SC 13G/A 1 d658097dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this State
February 13, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / HBM Healthcare Investments (Cayman) Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm245871d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Longboard Pharmaceuticals, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) February 6, 2024 (Date of Event Which Requires Filing of th
January 30, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 lbph13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) * Longboard Pharmaceuticals, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Che
January 29, 2024	SC 13D/A	LBPH / Longboard Pharmaceuticals, Inc. / PFIZER INC - SC 13D/A LONGBOARD PHARMACEUTICALS Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc
January 26, 2024	SC 13G/A	LBPH / Longboard Pharmaceuticals, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 LBPHSC13GA2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 54300N103 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check t
January 12, 2024	SC 13G	LBPH / Longboard Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm243266d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 54300N103 (CUSIP Number) January 2, 2024 (Date of Event Which Requires Filing of this Statement)
January 10, 2024	SC 13D/A	LBPH / Longboard Pharmaceuticals, Inc. / PFIZER INC - SC 13D/A LONGBOARD PHARMACEUTICALS Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc
January 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Longboard Pharmac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Co
January 4, 2024	EX-1.1	Underwriting Agreement by and among the Company, Cantor Fitzgerald & Co. and Citigroup Global Markets Inc. dated January 3, 2024 Exhibit 1.1 LONGBOARD PHARMACEUTICALS, INC. (Delaware corporation) 10,000,000 Shares of Voting Common Stock UNDERWRITING AGREEMENT Dated: January 3, 2024 LONGBOARD PHARMACEUTICALS, INC. (Delaware corporation) 10,000,000 Shares of Voting Common Stock UNDERWRITING AGREEMENT January 3, 2024 Cantor Fitzgerald & Co. Citigroup Global Markets Inc. as Representatives of the several Underwriters c/o Cantor
January 4, 2024	424B5	10,000,000 Shares of Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Nos. 333-273712, 333-267674 and 333-276369 PROSPECTUS SUPPLEMENT (To Prospectuses Dated August 11, 2023 and October 11, 2022) 10,000,000 Shares of Common Stock We are offering 10,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “LBPH.” The last reported sale price of our
January 3, 2024	S-3MEF	As filed with the Securities and Exchange Commission on January 3, 2024 S-3MEF As filed with the Securities and Exchange Commission on January 3, 2024 Registration No.
January 3, 2024	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Longboard Pharmaceuticals, Inc.
January 2, 2024	EX-99.2	EX-99.2 1 LONGBOARD PHARMACEUTICALS PACIFIC Study Topline Data JANUARY 2, 2024 Exhibit 99.
January 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Longboard Pharmac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Co
January 2, 2024	EX-99.2	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: the potential of LP352 (including to be best-in-class, to cha PACIFIC Study Topline Data January 2, 2024 Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: the potential of LP352 (including to be best-in-class, to change the DEE landscape, to serve as the cornerstone of a potential world-class epilepsy franchi
January 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Longboard Pharmac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Comm
January 2, 2024	424B5	Subject to completion, dated January 2, 2024 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Nos. 333-273712 and 333-267674 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not a
January 2, 2024	EX-99.1	Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) • Bexicaserin achieved a median seizure r Exhibit 99.1 Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) • Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population • A median seizure r
November 29, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Co
November 29, 2023	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; our develop Corporate Presentation November 29, 2023 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; our development approach and position to have best-in-class drug candidates; anticipated milestones; the pr
November 2, 2023	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results • LP352 Phase 1b/2a PACIFIC Study enrollment completed in August 2023 with topline data on track for January 2024 • LP659 first-in-human Phase 1 single-ascending dose (SAD) study initiation expected Q4 2023, with topline data expected in the first half 2024 LA JOLLA, Calif., November 2
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longb
November 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
October 11, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
October 11, 2023	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; our develop Slides from a presentation titled “Investor & Analyst Event October 11, 2023 Exhibit 99.
September 22, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (C
September 22, 2023	EX-3.1	Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K (File No. 001-40192) filed with the SEC on September 22, 2023). Exhibit 3.1 AMended and restated BYLAWS OF Longboard Pharmaceuticals, Inc. September 21, 2023 ARTICLE I Offices TC Section 1. Registered Office TC . The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices TC . The corporation shall also have and maintain an office or principal place of business at such pla
August 23, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Comm
August 23, 2023	EX-99.1	Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies Exhibit 99.1 Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies • Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study • Participants have a broad range of DEEs including Lennox-Gastaut syndrome, Dravet syndrome, SCN2A-related epilepsies, C
August 9, 2023	CORRESP	Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 August 9, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky RE: Longboard Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 4, 2023 File No. 333-273712 Ladies and Gentlemen: Pursuant to Rul
August 4, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
August 4, 2023	EX-4.5	Form of Indenture. EX-4.5 Exhibit 4.5 LONGBOARD PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Ce
August 4, 2023	424B5	Up to $75,000,000 of Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267674 PROSPECTUS SUPPLEMENT (To Prospectus dated October 11, 2022) Up to $75,000,000 of Shares of Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock, $0.0001 par value per share, offered
August 4, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Longboard Pharmaceuticals, Inc.
August 4, 2023	EX-4.9	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 LONGBOARD PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF LONGBOARD PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national bankin
August 4, 2023	S-3	As filed with the Securities and Exchange Commission on August 4, 2023 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2023 Registration No.
August 4, 2023	EX-4.10	Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.10 Exhibit 4.10 LONGBOARD PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF LONGBOARD PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national bank
August 4, 2023	EX-4.8	Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 LONGBOARD PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF LONGBOARD PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associa
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
August 3, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
August 3, 2023	EX-10.1	Non-Employee Director Compensation Policy, as amended and restated May 25, 2023. Exhibit 10.1 LONGBOARD PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY AMENDED AND RESTATED: MAY 25, 2023 Each member of the Board of Directors (the “Board”) of Longboard Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of to the Company or any of its subsidiaries and who is designated by the Board or the Compensation Committee of the Board as eligible t
August 3, 2023	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results • LP352 Phase 1b/2a PACIFIC Study enrollment completion expected this summer with topline data expected around year-end 2023 • Ended second quarter 2023 with $63.0 million in cash, cash equivalents and investments; cash runway is expected to support operations into mid-2024 LA JOLLA,
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Longboard Pharmaceut UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commiss
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
May 9, 2023	EX-99	Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results • LP352 Phase 1b/2a PACIFIC Study topline data expected in fourth quarter 2023 • LP659 IND submitted to FDA after incorporating input from a pre-IND meeting; Phase 1 initiation of first in-human clinical study on track for second quarter 2023, with Phase 1 topline single-ascending dose
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Longboard Pharmaceuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commissi
April 20, 2023	SC 13G	LBPH / Longboard Pharmaceuticals Inc / Prosight Management, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) April 12, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d
April 20, 2023	EX-99.1	JOINT FILING AGREEMENT April 19, 2023 EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT April 19, 2023 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule or regulation thereunder (includ
April 11, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 11, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 27, 2023	SC 13D/A	LBPH / Longboard Pharmaceuticals Inc / PFIZER INC - SC 13D/A LONGBOARD PHARMACEUTICALS Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc
March 2, 2023	EX-99	Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives Exhibit 99.1 Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives • LP352 Phase 1b/2a PACIFIC Study remains on track to complete enrollment in the first half of 2023, with topline data expected in the second half of 2023 • LP659 Phase 1 initiation of first in-human clinical study on track for first half of 2023, with Phase 1 topline single-ascending dose
March 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Longboard Pharmaceu UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commis
March 2, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40192 Longboard Pharm
March 2, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Longboard Pharmaceuticals, Inc.
March 2, 2023	S-8	As filed with the Securities and Exchange Commission on March 2, 2023 S-8 1 d465995ds8.htm S-8 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Longboard Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 84-5009619 (State or other jurisdiction of incorpo
February 14, 2023	SC 13G/A	LBPH / Longboard Pharmaceuticals Inc / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Longboard Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 54300N103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig
February 14, 2023	SC 13G/A	LBPH / Longboard Pharmaceuticals Inc / HBM Healthcare Investments (Cayman) Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm235913d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Longboard Pharmaceuticals, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of t
February 14, 2023	SC 13G	LBPH / Longboard Pharmaceuticals Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 l021323a.htm SCHEDULE 13G 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Longboard Pharmaceuticals, Inc. (Title of Class of
February 14, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 l021323b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf
February 8, 2023	EX-1.1	Underwriting Agreement by and among the Company, Evercore Group L.L.C. and Cantor Fitzgerald & Co. dated February 7, 2023 EX-1.1 2 lbph-ex11.htm EX-1.1 Exhibit 1.1 LONGBOARD PHARMACEUTICALS, INC. (Delaware corporation) 5,000,000 Shares of Voting Common Stock UNDERWRITING AGREEMENT Dated: February 7, 2023 LONGBOARD PHARMACEUTICALS, INC. (Delaware corporation) 5,000,000 Shares of Voting Common Stock UNDERWRITING AGREEMENT February 7, 2023 Evercore Group L.L.C. Cantor Fitzgerald & Co. as Representatives of the several U
February 8, 2023	424B5	5,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267674 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 11, 2022) 5,000,000 Shares Common Stock We are offering 5,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “LBPH.” The last reported sale price of our common stock on the Nasdaq Global Market on February 7, 2023
February 8, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
February 7, 2023	424B5	Subject to completion, dated February 7, 2023 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-267674 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
February 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Longboard Pharma UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
February 3, 2023	SC 13G/A	LBPH / Longboard Pharmaceuticals Inc / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 25, 2023	SC 13G/A	LBPH / Longboard Pharmaceuticals Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 54300N103 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to desig
December 5, 2022	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our future results of operations and financial position; busi Corporate Presentation - The Potential of LP352 December 2022 CONFIDENTIAL Exhibit 99.
December 5, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longb
November 3, 2022	EX-10.1	Second Amendment, dated September 13, 2022, to Arena License Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 10-Q (File No. 001-40192), filed with the SEC on November 3, 2022). Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment to License Agreement (this “Second Amendment”) is entered into as of September 13, 2022 (the “Second Amendment Date”) by and between
November 3, 2022	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results • LP352 Phase 1b/2a PACIFIC Study in participants with a range of developmental and epileptic encephalopathies (DEEs) ages 12-65 on track for topline data in second half 2023 • Phase 1 open-label study to assess central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (P
November 3, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Longboard Pharma UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
October 5, 2022	CORRESP	Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 Longboard Pharmaceuticals, Inc. 4275 Executive Square, Suite 950 La Jolla, California 92037 October 5, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara RE:?Longboard Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed September 30, 2022 File No. 333-267674 Ladies and Gentlemen: Pursuant
October 3, 2022	LETTER	LETTER United States securities and exchange commission logo October 3, 2022 Brandi Roberts Chief Financial Officer Longboard Pharmaceuticals, Inc.
September 30, 2022	EX-4.8	Form of Common Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.8 LONGBOARD PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 LONGBOARD PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking association] organi
September 30, 2022	EX-4.5	Form of Indenture. EXHIBIT 4.5 LONGBOARD PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certifica
September 30, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Longboard Pharmaceuticals, Inc.
September 30, 2022	EX-4.9	Form of Preferred Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.9 LONGBOARD PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20 LONGBOARD PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking associatio
September 30, 2022	EX-4.10	Form of Debt Securities Warrant Agreement and Warrant Certificate. EXHIBIT 4.10 LONGBOARD PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 LONGBOARD PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of between LONGBOARD PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and , a [corporation] [national banking associati
September 30, 2022	S-3	As filed with the Securities and Exchange Commission on September 30, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 30, 2022 Registration No.
September 30, 2022	EX-1.2	Controlled Equity OfferingSM Sales Agreement, dated as of September 30, 2022, by and between the Registrant and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit 1.2 to the Registrant's Registration Statement on Form S-3 (File No. 267674), filed with the SEC on September 30, 2022) Exhibit 1.2 Longboard Pharmaceuticals, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement September 30, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Longboard Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?),
September 19, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (C
August 4, 2022	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results EX-99.1 2 lbph-ex991.htm EX-99.1 Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results • LP352 Phase 1b/2a PACIFIC Study remains on track for completion in the second half of 2023; recently expanded the participant age range to 12-65 years old and added open-label extension study • Initiated a Phase 1 open-label study to assess central n
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
May 24, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commiss
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
May 5, 2022	EX-10.3	Employment Agreement by and between the Registrant and Randall E. Kaye, M.D., dated March 17, 2022 (incorporated by reference to Exhibit 10.3 to the Registrant’s Form 10-Q (File No. 001-40192), filed with the SEC on May 5, 2022). Exhibit 10.3 March 17, 2022 Randall E. Kaye, M.D. via email Re: Offer of Employment Dear Randall: Longboard Pharmaceuticals, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Chief Medical Officer (“CMO”) under the terms and conditions set forth in this employment agreement (the “Agreement”). 1. Employment by the Company. Your employment with the Company shall comm
May 5, 2022	EX-10.2	Retirement and Consulting Agreement by and between the Registrant and Philip Perera, M.D., dated March 17, 2022 Exhibit 10.2 March 17, 2022 Philip Perera Via email Re: Retirement and Consulting Agreement Dear Philip: This letter sets forth the substance of the retirement and consulting agreement (the “Agreement”) that Longboard Pharmaceuticals, Inc. (“Longboard”)) is offering to you in connection with your employment termination. 1. Retirement and Employment Resignation. You have informed Longboard that you
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commissi
May 5, 2022	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results EX-99.1 2 lbph-ex991.htm EX-99.1 Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results • Phase 1 data for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies, presented at the American Academy of Neurology (AAN) Annual Meeting • Initiated Phase 1b/2a PACIFIC Study evaluating LP352 for participants
April 13, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte
April 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 21, 2022	SC 13D	LBPH / Longboard Pharmaceuticals Inc / PFIZER INC - SC 13D LONGBOARD PHARMACEUTICALS Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 54300N103 (CUSIP Number) Margaret M. Madden, Esq. Senior Vice President and Corporate Secretary, Chief Governance Counsel Pfizer Inc. 235 East 42nd Str
March 21, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
March 21, 2022	EX-1	JOINT FILING AGREEMENT EX-1 2 longboardexh1.htm EX 1 JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing of Statement on Schedule 13D (including subsequent amendments thereto) with respect to the common stock, par value $0.0001 per share, of Longboard Pharmaceuticals, Inc. and
March 21, 2022	EX-1	JOINT FILING AGREEMENT EX-1 2 longboardexh1.htm EX 1 JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing of Statement on Schedule 13D (including subsequent amendments thereto) with respect to the common stock, par value $0.0001 per share, of Longboard Pharmaceuticals, Inc. and
March 10, 2022	SC 13G	LBPH / Longboard Pharmaceuticals Inc / ARENA PHARMACEUTICALS INC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.
March 3, 2022	S-8	Power of Attorney (included on the signature page). As filed with the Securities and Exchange Commission on March 3, 2022 Registration No.
March 3, 2022	EX-10.14	First Amendment, dated January 28, 2022, to Arena License Agreement (incorporated by reference to Exhibit 10.14 to the Registrant’s Form 10-K (File No. 001-40192), filed with the SEC on March 3, 2022). Exhibit 10.14 FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment to License Agreement (this ?First Amendment?) is entered into as of January 28, 2022 (the ?First Amendment Date?) by and between Arena Pharmaceuticals, Inc., a Delaware corporation (?Licensor?), and Longboard Pharmaceuticals, Inc., a Delaware corporation (?Licensee?), each individually a ?Party? and together, the ?Parties?. Fo
March 3, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Longboard Pharmaceuticals, Inc.
March 3, 2022	EX-4.3	Exhibit 4.3 Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the common stock of Longboard Pharmaceuticals, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this ?Description of Common Stock,? you should refer to our amen
March 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commis
March 3, 2022	EX-10.14	First Amendment, dated January 28, 2022, to Arena License Agreement (incorporated by reference to Exhibit 10.14 to the Registrant’s Form 10-K (File No. 001-40192), filed with the SEC on March 3, 2022). Exhibit 10.14 FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment to License Agreement (this ?First Amendment?) is entered into as of January 28, 2022 (the ?First Amendment Date?) by and between Arena Pharmaceuticals, Inc., a Delaware corporation (?Licensor?), and Longboard Pharmaceuticals, Inc., a Delaware corporation (?Licensee?), each individually a ?Party? and together, the ?Parties?. Fo
March 3, 2022	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results ? Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs) ? LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndrome ? LP6
March 3, 2022	EX-4.3	Exhibit 4.3 Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the common stock of Longboard Pharmaceuticals, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this ?Description of Common Stock,? you should refer to our amen
March 3, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40192 Longboard Pharm
March 3, 2022	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results ? Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs) ? LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndrome ? LP6
March 3, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Longboard Pharmaceuticals, Inc.
February 14, 2022	SC 13G/A	LBPH / Longboard Pharmaceuticals Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Longboard Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 54300N103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
February 3, 2022	SC 13G/A	LBPH / Longboard Pharmaceuticals Inc / FARALLON CAPITAL MANAGEMENT LLC - AMENDMENT #1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 12, 2022	SC 13G	LBPH / Longboard Pharmaceuticals Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LONGBOARD PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 54300N103 (CUSIP Number) JANUARY 6, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
January 10, 2022	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our future results of operations and financial position; busi January 2022 Corporate Presentation Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (?we,? ?Longboard? or the ?Company?), including statements regarding: our future results of operations and financial position; business strategy; the timing, costs and conduct of our preclinical studies and clinical trials for our p
January 10, 2022	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our future results of operations and financial position; busi January 2022 Corporate Presentation Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (?we,? ?Longboard? or the ?Company?), including statements regarding: our future results of operations and financial position; business strategy; the timing, costs and conduct of our preclinical studies and clinical trials for our p
December 1, 2021	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our future results of operations and financial position; busi December 2021 Corporate Presentation Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (?we,? ?Longboard? or the ?Company?), including statements regarding: our future results of operations and financial position; business strategy; the timing, costs and conduct of our preclinical studies and clinical trials for our
December 1, 2021	EX-99.1	Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our future results of operations and financial position; busi December 2021 Corporate Presentation Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (?we,? ?Longboard? or the ?Company?), including statements regarding: our future results of operations and financial position; business strategy; the timing, costs and conduct of our preclinical studies and clinical trials for our
December 1, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
November 17, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Co
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longb
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Com
November 4, 2021	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results ? Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies ? Initiating a Phase 1b/2a clinical trial evaluating LP352 in approximately 50 participants with d
November 4, 2021	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results ? Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies ? Initiating a Phase 1b/2a clinical trial evaluating LP352 in approximately 50 participants with d
September 8, 2021	EX-99.1	Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial Exhibit 99.1 Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial ? Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed ? Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin ? Company plans
September 8, 2021	EX-99.1	Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial Exhibit 99.1 Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial ? Favorable safety, tolerability, pharmacokinetics and pharmacodynamics were observed ? Central 5-HT2c receptor engagement demonstrated by dose- and exposure-dependent increases of prolactin ? Company plans
September 8, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Co
August 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Longboard Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 1-40192 84-5009619 (State or Other Jurisdiction of Incorporation) (Commi
August 9, 2021	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results ? Continued progress with the multiple ascending dose (MAD) portion of the Phase 1 clinical trial for LP352, a potential treatment for severe epileptic indications, with topline results expected in 2021 ? Initiated a number of IND-enabling preclinical studies for LP143 and LP659 ? Est
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
August 9, 2021	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results ? Continued progress with the multiple ascending dose (MAD) portion of the Phase 1 clinical trial for LP352, a potential treatment for severe epileptic indications, with topline results expected in 2021 ? Initiated a number of IND-enabling preclinical studies for LP143 and LP659 ? Est
May 10, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40192 Longboard
May 10, 2021	EX-99.1	Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results Exhibit 99.1 Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results ? Commenced multiple ascending dose (MAD) portion of the Phase 1 study for LP352, a potential treatment for severe epileptic indications; topline results expected in the second half of 2021 ? Successfully completed an upsized initial public offering (IPO) raising approximately $84.8 mi
May 10, 2021	EX-3.2	Amended and Restated Bylaws of the Registrant. Exhibit 3.2 AMended and restated BYLAWS OF Longboard Pharmaceuticals, Inc. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corp

LBPH / Longboard Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)